M-009
(±)-Methamphetamine solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
About This Item
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
drug control
Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
forensics and toxicology
format
single component solution
storage temp.
−20°C
SMILES string
CC(NC)CC1=CC=CC=C1
InChI
1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3
InChI key
MYWUZJCMWCOHBA-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
Application
- Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional, and biochemical consequences in the rat brain: This research explores the utility of (±)-Methamphetamine in neurochemical studies, specifically examining its epigenetic, transcriptional, and biochemical impacts on the rat brain over short and long periods. The study underscores the importance of methamphetamine as a research chemical in understanding addiction and relapse mechanisms (Elhadi K, et al., 2023).
- Vaccines as Immunotherapies for Substance Use Disorders: This review highlights innovative approaches using (±)-Methamphetamine in the development of vaccines aimed at treating substance use disorders. It exemplifies cutting-edge pharmaceutical applications in creating immunotherapies to combat addiction (Kosten TR, 2024).
- The reflections of health service providers on implementing contingency management for methamphetamine use disorder in Australia: This article discusses the practical applications of (±)-Methamphetamine in contingency management strategies for treating methamphetamine use disorders, reflecting on real-world challenges and solutions from healthcare providers (Clay S, et al., 2024).
- Correction: PrEP Uptake and Methamphetamine Use Patterns in a 4-Year U.S. National Prospective Cohort Study of Sexual and Gender Minority People, 2017-2022: This correction notice relates to a study that investigates patterns of methamphetamine use and its implications in public health, especially in preventive medicine strategies among sexual and gender minority groups (Guo Y, et al., 2024).
- Identification of the circRNA-miRNA-mRNA network for treating methamphetamine-induced relapse and behavioral sensitization with cannabidiol: This research demonstrates the use of (±)-Methamphetamine to explore the genomic and molecular pathways involved in drug addiction and relapse, offering insights into potential treatments using cannabidiol (Liu L, et al., 2024).
Legal Information
related product
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Target Organs
Eyes,Central nervous system
WGK
WGK 2
Flash Point(F)
closed cup
Flash Point(C)
closed cup
Regulatory Information
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Protocols
Optimized sample prep and chiral chromatography methods for the LC/MS analysis of these drug enantiomers in urine
In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service